PT  - JOURNAL ARTICLE
AU  - Paoletti, Giovanni
AU  - Pepys, Jack
AU  - Casini, Marta
AU  - Di Bona, Danilo
AU  - Heffler, Enrico
AU  - Goh, Celine Y.Y.
AU  - Price, David B.
AU  - Canonica, Giorgio Walter
TI  - Biologics in severe asthma: the role of real-world evidence from registries
AID  - 10.1183/16000617.0278-2021
DP  - 2022 Jun 30
TA  - European Respiratory Review
PG  - 210278
VI  - 31
IP  - 164
4099  - http://err.ersjournals.com/content/31/164/210278.short
4100  - http://err.ersjournals.com/content/31/164/210278.full
SO  - EUROPEAN RESPIRATORY REVIEW2022 Jun 30; 31
AB  - Asthma is one of the most common noncommunicable diseases; in the majority of patients it is well controlled with inhaled bronchodilators and inhaled corticosteroids, but the management of severe asthma has been a significant challenge historically. The introduction of novel biologic drugs in the past few decades has revolutionised the field, presenting physicians with a variety of biologic drugs with different mechanisms for the treatment of severe asthma.It is of crucial importance to evaluate the effectiveness of these drugs by following their “real-life” effectiveness rather than relying solely on their efficacy, established in carefully designed clinical trials, which therefore do not necessarily match the profile of the real-life patient. Understanding the actual effectiveness of the specific drugs in real-life patients is a crucial part of tailoring the right drugs to the right patients. Registries serve as an important tool in obtaining real-life evidence, since they are in effect observational studies, following the entire patient population.Data on long-term efficacy and safety of biologics in severe asthma cannot be obtained by RCTs alone. Real-life studies should be a valuable source of this kind of information. https://bit.ly/3vM8AaD